Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Victorian Clinical Genetics Services, |
RCV002471613 | SCV002769016 | pathogenic | Neurofibromatosis, type 1 | 2022-02-02 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with NF1-related conditions. (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. A child may be more severely affected than a carrier parent (GeneReviews). (I) 0200 - Variant is predicted to result in a missense amino acid change from phenylalanine to leucine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated tubulin binding domain (PMID:34080803). (I) 0702 - Other missense variants comparable to the one identified in this case have strong previous evidence for pathogenicity. At least three alternative amino acid changes have been reported as pathogenic in unrelated individuals with NF1-related conditions, including one de novo report (Clinvar, DECIPHER, PMID:23244495, 11735023). (SP) 0803 - This variant has limited previous evidence of pathogenicity in an unrelated individual with neurofibromatosis type 1 (ClinVar, PMID:34080803). (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |